Avalo Therapeutics Inc (AVTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$19.23+1.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | — | 0.1 | 0.4 |
| Operating Expenses & Income | |||
| Operating Income | (91.4) | (72.9) | (68.5) |
| Earnings from Continuing Operations | |||
| Other Non-Operating Income / Expenses | (8.8) | (5.2) | 33.5 |
| EBT, Incl. Unusual Items | (100.2) | (78.1) | (35.0) |
| Income Tax Expense | 0.2 | 0.2 | 0.1 |
| Net Income | |||
| Net Income | (100.3) | (78.3) | (35.1) |
| Per Share | |||
| Basic EPS | (2.30) | (5.84) | (7.94) |
| Diluted EPS | (2.30) | (5.84) | (20.91) |
| Basic Weighted Avg Shares | 43.6 | 13.4 | 4.4 |
| Diluted Weighted Avg Shares | 43.6 | 13.4 | 7.5 |
| Supplemental | |||
| EBITDA | — | (72.6) | (68.3) |
| EBIT | (91.4) | (72.9) | (68.5) |
| Effective Tax Rate | -0.2% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.